WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
-0.99%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$10.4B
AUM Growth
-$393M
(-3.6%)
Cap. Flow
-$94.4M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
14.8%
Holding
711
New
186
Increased
182
Reduced
155
Closed
168
Top Buys
| 1 |
Marsh & McLennan
MMC
|
+$123M |
| 2 |
Electronic Arts
EA
|
+$102M |
| 3 |
Chord Energy
CHRD
|
+$100M |
| 4 |
Quest Diagnostics
DGX
|
+$89.2M |
| 5 |
Sensata Technologies
ST
|
+$73.8M |
Top Sells
| 1 |
Analog Devices
ADI
|
+$138M |
| 2 |
Avnet
AVT
|
+$131M |
| 3 |
ERF
Enerplus Corporation
ERF
|
+$110M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$73.5M |
| 5 |
Amazon
AMZN
|
+$73.3M |
Sector Composition
| 1 | Healthcare | 42.62% |
| 2 | Technology | 19.87% |
| 3 | Energy | 7.88% |
| 4 | Industrials | 7.25% |
| 5 | Financials | 7.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
FIVE9
FIVN
$2B
| $2.42M | 0.02% |
54,835
-83,219
| -60% | -$3.67M |
|
402
Clorox
CLX
$15.1B
| $2.4M | 0.02% |
17,604
-22,143
| -56% | -$3.02M |
|
403
ARS Pharmaceuticals
SPRY
$1.04B
| $2.39M | 0.02% |
281,144
-120,644
| -30% | -$1.03M |
|
404
Exact Sciences
EXAS
$10.3B
| $2.39M | 0.02% |
56,460
-137,814
| -71% | -$5.82M |
|
405
Voyager Therapeutics
VYGR
$227M
| $2.37M | 0.02% |
300,000
| – | – |
|
406
Taysha Gene Therapies
TSHA
$887M
| $2.3M | 0.02% |
+1,026,269
| New | +$2.3M |
|
407
Paychex
PAYX
$48.1B
| $2.17M | 0.02% |
+18,308
| New | +$2.17M |
|
408
First Advantage
FA
$2.78B
| $2.07M | 0.02% |
128,610
-63,274
| -33% | -$1.02M |
|
409
Reviva Pharmaceuticals
RVPH
$30.5M
| $2.04M | 0.02% |
1,592,788
+537,779
| +51% | +$688K |
|
410
Tourmaline Bio
TRML
$1.22B
| $2.03M | 0.02% |
157,947
+588
| +0.4% | +$7.56K |
|
411
Datadog
DDOG
$50.1B
| $1.97M | 0.02% |
15,179
-540,135
| -97% | -$70.1M |
|
412
Centuri Holdings
CTRI
$1.97B
| $1.95M | 0.02% |
+100,000
| New | +$1.95M |
|
413
Perrigo
PRGO
$3.05B
| $1.95M | 0.02% |
75,819
| – | – |
|
414
Brighthouse Financial
BHF
$2.69B
| $1.94M | 0.02% |
44,737
-31,519
| -41% | -$1.37M |
|
415
Neurocrine Biosciences
NBIX
$14.1B
| $1.93M | 0.02% |
14,011
-109,231
| -89% | -$15M |
|
|
TEM
416
Tempus AI, Inc. Class A Common Stock
TEM
$13.8B
| $1.93M | 0.02% |
+55,000
| New | +$1.93M |
|
417
VanEck Semiconductor ETF
SMH
$28.5B
| $1.9M | 0.02% |
+7,300
| New | +$1.9M |
|
418
Progress Software
PRGS
$1.85B
| $1.89M | 0.02% |
34,830
-10,745
| -24% | -$583K |
|
419
Middleby
MIDD
$7.04B
| $1.88M | 0.02% |
+15,314
| New | +$1.88M |
|
420
ArriVent BioPharma
AVBP
$764M
| $1.86M | 0.02% |
100,000
| – | – |
|
|
AGEN
421
Agenus
AGEN
$159M
| $1.85M | 0.02% |
+110,207
| New | +$1.85M |
|
422
Hubbell
HUBB
$24B
| $1.83M | 0.02% |
5,011
-21,215
| -81% | -$7.75M |
|
423
Cabaletta Bio
CABA
$154M
| $1.82M | 0.02% |
242,981
+318
| +0.1% | +$2.38K |
|
424
Rhythm Pharmaceuticals
RYTM
$6.69B
| $1.82M | 0.02% |
44,247
-127,960
| -74% | -$5.25M |
|
425
Zura Bio
ZURA
$138M
| $1.81M | 0.02% |
+515,899
| New | +$1.81M |
|